When.com Web Search

  1. Ads

    related to: her2 amplification vs overexpression left side of heart

Search results

  1. Results From The WOW.Com Content Network
  2. HER2 - Wikipedia

    en.wikipedia.org/wiki/HER2

    HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration are high, for instance in cancer. [8] Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer .

  3. Trastuzumab - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab

    Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. [30] Other severe side effects include heart failure, allergic reactions, and lung disease. [30] Use during pregnancy may harm the baby. [22] Trastuzumab works by binding to the HER2 receptor and slowing down cell replication. [30]

  4. Epidermal growth factor receptor - Wikipedia

    en.wikipedia.org/wiki/Epidermal_growth_factor...

    The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer. [6]

  5. ErbB - Wikipedia

    en.wikipedia.org/wiki/ErbB

    ErbB2 overexpression can occur in breast, ovarian, bladder, non-small-cell lung carcinoma, as well as several other tumor types. [28] Trastuzumab or Herceptin inhibits downstream signal cascades by selectively binding to the extracellular domain of ErbB-2 receptors to inhibit it. [28] This leads to decreased proliferation of tumor cells. [28]

  6. Cancer pharmacogenomics - Wikipedia

    en.wikipedia.org/wiki/Cancer_Pharmacogenomics

    [19] [20] Trastuzumab, the first HER2-targeted drug developed in 1990, interferes with HER2 signalling. In 2001, a study showed that adding trastuzumab to chemotherapy improved overall survival in women with HER2-positive metastatic breast cancer. [21] Then, in 2005, it was shown that trastuzumab is effective as an adjuvant treatment in women ...

  7. Endocrine therapy resistance in breast cancer - Wikipedia

    en.wikipedia.org/wiki/Endocrine_therapy...

    The overexpression of HER2 is determined by immunohistochemistry (IHC), or with fluorescent in situ hybridization in those equivocal cases where IHC does not provide a clear result. Different molecular subtypes of breast cancer have also been described, which loosely align with receptor status: Luminal A (ER and/or PR positive; HER2 negative)

  1. Ads

    related to: her2 amplification vs overexpression left side of heart